717878-06-3

Basic information

• Product Name: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole
• Synonyms: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole
• CAS NO: 717878-06-3
• Molecular Formula: C₉H₆FN₃O₂
• Molecular Weight: 207.1612432
• Mol File: 717878-06-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 366.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.29±0.61(Predicted)
• CAS DataBase Reference: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(717878-06-3)
• EPA Substance Registry System: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(717878-06-3)

Safety Data

• Hazardous Substances Data: 717878-06-3(Hazardous Substances Data)

Usage

General Description

1-(4-fluorophenyl)-4-nitro-1H-imidazole is a chemical compound with the molecular formula C9H6FN3O2. It is a nitroimidazole derivative, which is a class of compounds known for their antimicrobial and antiprotozoal properties. The compound contains a nitro group and a fluorophenyl group, which are both known to have biological activity in medicinal chemistry. 1-(4-fluorophenyl)-4-nitro-1H-imidazole may have potential applications in the development of new drugs for treating microbial infections and parasitic diseases. Further research is needed to fully understand its pharmacological properties and potential therapeutic uses.

Upstream product

• 19182-81-1 1,4-dinitro-1H-imidazole 
• 371-40-4 4-fluoroaniline 

Relevant articles and documents

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds

Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure-activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic